What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
His primary scientific interests are in Internal medicine, Surgery, Scleroderma, Scleroderma Renal Crisis and Connective tissue disease.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Cardiology.
His Surgery research includes themes of Clinical trial, Rheumatoid arthritis and Cohort.
The concepts of his Scleroderma study are interwoven with issues in Respiratory disease and Kidney.
His Connective tissue disease study integrates concerns from other disciplines, such as Systemic disease, Immunopathology and Proportional hazards model.
His study in Rheumatology is interdisciplinary in nature, drawing from both Anti–citrullinated protein antibody, Rheumatoid factor, Rheumatoid vasculitis, Disease-modifying antirheumatic drug and Rheumatoid nodule.
His most cited work include:
- The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. (16871 citations)
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee (5001 citations)
- Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. (3169 citations)
What are the main themes of his work throughout his whole career to date?
Thomas A. Medsger mainly focuses on Internal medicine, Scleroderma, Immunology, Surgery and Pathology.
His Internal medicine research integrates issues from Gastroenterology and Cardiology.
His Scleroderma study is concerned with the larger field of Dermatology.
Thomas A. Medsger has included themes like Adverse effect, Clinical trial, Rheumatoid arthritis and Cohort in his Surgery study.
His research investigates the connection between Clinical trial and topics such as Randomized controlled trial that intersect with problems in Physical therapy.
His work deals with themes such as Systemic disease, Immunopathology and Pathogenesis, which intersect with Connective tissue disease.
He most often published in these fields:
- Internal medicine (42.96%)
- Scleroderma (41.52%)
- Immunology (23.47%)
What were the highlights of his more recent work (between 2010-2021)?
- Internal medicine (42.96%)
- Scleroderma (41.52%)
- Immunology (23.47%)
In recent papers he was focusing on the following fields of study:
Thomas A. Medsger mostly deals with Internal medicine, Scleroderma, Immunology, Pathology and Cohort.
His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine.
His Surgery research is multidisciplinary, relying on both Carcinoma and Azotemia.
The subject of his Scleroderma research is within the realm of Dermatology.
He has researched Dermatology in several fields, including External validation and Penicillamine.
His work carried out in the field of Pathology brings together such families of science as Physical therapy and Transforming growth factor beta.
Between 2010 and 2021, his most popular works were:
- Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial (320 citations)
- Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma (162 citations)
- Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis (139 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Thomas A. Medsger mainly investigates Internal medicine, Scleroderma, Pathology, Immunology and Physical therapy.
His Internal medicine study often links to related topics such as Surgery.
His Surgery study incorporates themes from Pulmonary hypertension and Cardiology.
His Scleroderma research is multidisciplinary, incorporating elements of Epidemiology, Young adult, Autoantibody, Connective tissue disease and Pulmonary fibrosis.
As a part of the same scientific study, Thomas A. Medsger usually deals with the Pathology, concentrating on Antibody and frequently concerns with Peripheral blood.
As part of one scientific family, he deals mainly with the area of Physical therapy, narrowing it down to issues related to the Clinical trial, and often Skin score.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
